

PATIENT DETAILS				
Patient name:	DOB:	Phone:		
Address:				
Medicare:	Clinical trial	/ ID no.:		
EXAMINATION				
PET PSMA with Whole Body Diagnostic CT (Head, Chest, Abdo, Pelvis) Plus Extremity (eg. Melanoma, Sarcoma, Myeloma, PUO, Vasculitis/Arteritis, Rheumatological or where limb involvement suspected)				
 □ PET PSMA with localised diagnostic CT (please tick region/s) □ Head □ Neck □ Chest □ Abdo □ Pelvis □ Extremity 				
☐ PET PSMA with Non-Diagnostic CT (attenuation correction)				
CLINICAL DETAILS		☐ Contrast Allergy		
Please insert value for at least one of the following: PSA (>10 ng/ml): Glea	son score (> or = 7):	Renal Impairment Surgery / Biopsy Radiation Therapy		
ISUP (> or = 2): Stag	e (> or = T2b):	☐ Chemotherapy		
☐ Non-Medicare eligible PSMA		Prior Imaging (when and where)		
Other clinical details:				
INITIAL STAGING - 61563				
The patient has intermediate to high-risk prostate adenocarcinoma				
☐ The patient has previously been untreated				
☐ The patient is considered suitable for locoregional therapy with curative intent				
RESTAGING - 61564				
☐ The patient has intermediate to high-risk prostate adenocarcinoma				
The patient has undergone prior locoregional therapy and is considered suitable for further locoregional therapy				
REFERRING PRACTITIONER				
Name:	Provider number:			
Address:				
Follow up appointment:	Send copy to:			
Signature:	Date:			

PSMA		
Initial staging	61563	Whole body prostate specific membrane antigen PET study performed for the initial staging of intermediate to high risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. Applicable once per lifetime.
Restaging	61564	Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who: (a) has undergone prior locoregional therapy; and (b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation
		This item can be claimed by patients with: a prostate specific antigen (PSA) increase of 2ng/ml above the nadir after radiation therapy; or failure of PSA levels to fall to undetectable levels; or rising PSA serum after a radical prostatectomy. Applicable twice per lifetime.

Qscan PET-CT locations



Qscan Annerley

7/310 lpswich Rd, Annerley 4103 **p:** 07 3357 0388 **f:** 07 3357 0380

Qscan Mackay

148 Sams Rd, North Mackay 4740 **p:** 07 4960 4940 **f:** 07 3144 5623

Qscan Maroochydore

Shop 5, 84 Wises Rd, Maroochydore 4558 **p:** 07 5220 8300 **f:** 07 5294 1010

Qscan North Lakes

9 McLennan Ct, North Lakes 4509 **p:** 07 3448 8840 **f:** 07 3880 6118

Qscan Southport

Pacific Private Clinic, 123 Nerang St, Southport 4215 p: 07 5503 3433 f: 07 5503 3444



Qscan University of Canberra

University of Canberra, Corner Broula &, Allawoona St, Bruce 2617 **p:** 02 6126 5080 **f:** 02 8322 4025

NSW

Qscan Westmead

2B Darcy Rd, Westmead 2145 **p:** 02 4761 4225 **f:** 02 8331 1920



Qscan Windsor Gardens

Level 1, 480 Specialist Centre, 480 North East Road, Windsor Gardens 5087

p: 08 8164 5600 **f:** 08 8164 5045



Qscan Hobart

2 Melville St, Hobart 7000 **p:** 03 6240 1940 **f:** 03 6231 4985



Qscan Midland

81 Yelverton Dr, Midland 6056 p: 08 6155 5500 f: 08 6266 3719

Qscan Rockingham

2 Civic Blvd, Rockingham 6168 **p:** 08 9500 8950 **f:** 08 6444 7480



BOOK AN APPOINTMENT

All images are digitally archived for ten years and can be accessed by your doctor online anytime.

Your doctor has recommended you attend Qscan Radiology Clinics. You may choose another provider but please discuss this with your doctor first.